Nutex Health Inc. (NUTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on September 22, 2025, regarding events occurring on September 16, 2025. Nutex Health Inc., a healthcare services company incorporated in Delaware, reported the appointment of a new Chief Operating Officer (COO) to replace a previously departed executive.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change is the appointment of Mr. Wesley Bamburg as Chief Operating Officer, effective on or about October 13, 2025. This follows the departure of Joshua DeTillio, disclosed in a July 11, 2025 filing.
Management Commentary, Risks, and Unusual Items
The filing details the terms of the two-year employment agreement with Mr. Bamburg:
- Base Salary: $415,000 annually, subject to annual review.
- Signing Bonus: $100,000, payable in four quarterly installments of $25,000, contingent on remaining employed for at least 12 months.
- Annual Bonus: Eligible for up to 60% of base salary based on company and individual goals.
- Long-Term Incentives: Eligible for participation in the company's long-term incentive plan, with potential RSU awards valued up to 60% of base salary.
- Severance: In the event of termination without cause or resignation for good reason, Mr. Bamburg is entitled to 12 months of base salary and 12 months of health benefits subsidies. No severance is payable for cause, resignation without good reason, death, or disability.
- Contract Term: Two-year initial term with automatic two-year extensions unless 60-day notice of non-extension is provided.
The filing states there are no family relationships between Mr. Bamburg and company directors or officers, and no undisclosed interests in transactions requiring reporting under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the commencement date of Mr. Bamburg's role (on or about October 13, 2025).
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause" and "good reason."
- Confirm the status of the previous COO, Joshua DeTillio, and any transition arrangements.
- Monitor future filings for the actual payout of the signing bonus and any RSU grants.